The CellSeal Automated Thawing System solves a vital aspect of cell-based therapy development
Enables detailed control in thawing of cell and gene therapies.
Cook Regentec, focused on developing research and clinical tools to advance regenerative medicine therapies from the lab to the patient, and Asymptote, specialists in cryochain for regenerative medicine, have launched the CellSeal Automated Thawing System. The new system, which has been developed as part of a collaboration between the two companies, provides users with thorough control in the thawing of cryogenically frozen cells, a critical step in the delivery of cell and gene therapies.
The CellSeal Automated Thawing System solves a vital and overlooked aspect of cell-based therapy development. The current practice of thawing these potentially fragile, living therapies relies on a manual process using a water bath. The new system works through dry conduction with no need of water, a potential source of contamination, and provides an effective, reliable and scalable solution which supports Good Manufacturing Practice (GMP) requirements.
The CellSeal Automated Thawing System has demonstrated performance. In a recent study with mesenchymal stem cells (MSC), the system consistently equaled viability results obtained from water bath thawing. The system’s effectiveness comes from the extraordinary control it provides over the thawing process. Therapy manufacturers can tune a thaw profile to suit the specific needs of their cellular therapy, then lock the profile down for one-touch repeatability. The system removes any user subjectivity by detecting the precise thaw end-point—extremely difficult to achieve using the standard water bath process. The technology offers manufacturers consistent control over the thawing process of their cell therapy.
An important feature of the new system is instant access to vital data. Until this new system, the collection and collation of data from thaw sites, often using paper records, could produce significant challenges to cell and gene therapy manufacturers. Now, data recording in each CellSeal® Automated Thawing System captures a record of the thaw process. With appropriate software, hardware and connectivity, this data can be viewed anywhere in the world to validate and implement a manufacturer’s end-to-end thawing protocol.
Brad King, Director of Advanced Laboratory Products at Cook Regentec, explained the challenge: “We created our CellSeal product line to support cell and gene therapy companies through every bioprocessing step. Thawing of cryopreserved therapies often happens outside the lab in conditions that up to now have been very difficult to control; thaw-site personnel have had to take great care to avoid contamination risks from the use of warm water. Also, manually produced records for thawing and administering the product at a remote site can take a long time to return to a manufacturer, if they are returned at all. The CellSeal Automated Thawing System makes it easy to ensure an effective, controlled and auditable thaw.”
Cook partnered with Asymptote for the technology behind the thawing system because of their long established cryopreservation expertise and innovative cryochain technologies for regenerative medicine.
John Morris, Asymptote CEO shared some details: “Today’s announcement builds on thawing technology we have been working on for over two years in collaboration with The Cell and Gene Therapy Catapult. Over that period, Asymptote built many different thawing engines for testing at the Catapult labs and captured requirements from a wide cross-section of stakeholders across the industry. By partnering that foundation with Cook Regentec’s development of closed-system vials, we’re able to offer the industry a unique level of control over the thawing process. No other solution allows the same flexibility to customise thawing settings in the lab, then lock them down for quick and easy operation every time after. Combine this with the ability to transmit a record of the entire process instantly to a web browser anywhere in the world, and you have a system that can give manufacturers complete confidence in their thawing protocol.“
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance